Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

A drug currently approved to improve blood sugar regulation in adults with type 2 diabetes is expected to be approved by the Food and Drug Administration (FDA) for weight loss this year—and there are ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

"Tirzepatide: The weight-loss drug that also shrinks breast tumors in mice." ScienceDaily. ScienceDaily, 13 July 2025. <www.sciencedaily.com / releases / 2025 / 07 / 250713031436.htm>.

CHICAGO — In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according to new data from the SURMOUNT-1 study. As Healio previously ...

Eli Lilly's weight-loss drug Zepbound (tirzepatide) just proven to be more effective than Novo Nordisk's Wegovy (semaglutide) in losing body weight.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Tirzepatide is sold under the brand names Mounjaro and Zepbound. This diabetes and weight loss drug can come with a high price tag. So, how much does tirzepatide cost?

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...